BACKGROUND: Giant intracranial arteriovenous malformations (AVMs) are rare cerebrovascular lesions that pose management challenges. OBJECTIVE: To further clarify outcomes in patients with giant cerebral AVMs managed with conservative or interventional therapies. METHODS: We performed a retrospective review of all patients diagnosed with AVMs evaluated at our institution from 1990 to 2013. Patients with a single intracranial AVM .6 cm were included. Patients were divided into 2 groups: conservative management or intervention (microsurgery, radiosurgery, or embolization). Functional outcome was assessed with the modified Rankin Scale (mRS) and compared between the 2 groups. RESULTS: A total of 55 patients with giant AVMs were included, and 35 patients (63.6%) had clinical follow-up with a mean of 11.8 years. Spetzler-Martin grades were as follows: grade III, n = 2 (3.6%); grade IV, n = 15 (27.3%); and grade V, n = 38 (69.1%). Twenty-four patients (43.6%) were conservatively managed. The patients in the conservatively managed group had larger AVMs (P , .05) with more frequent involvement of the temporal lobe (P = .02). Five patients (26.3%) in the conservatively managed group and 5 (31.3%) in the intervention group experienced hemorrhage during follow-up, translating to an annualized risk of 2.7% and 4.1%, respectively. No significant difference in risk of first subsequent hemorrhage was observed (P = .78). Despite comparable mRS scores at presentation, we observed a trend toward better outcomes (mRS , 2) in patients undergoing conservative management (P = .06) compared with the intervention group at last follow-up. CONCLUSION: This study suggests that interventions for giant AVMs should be considered cautiously because hemorrhagic risk is similar regardless of management strategy and functional outcome is likely to be same or better in the conservatively managed population.
G iant intracranial arteriovenous malformations (AVM) are defined as AVMs with a maximum diameter .6 cm. They constitute approximately 3.1% to 4.1% of all intracranial AVMs 1,2 and pose substantial management challenges because of their complex angioarchitecture, intractable symptoms, and frequent involvement of multiple eloquent brain regions. The clinical manifestations and natural history of giant AVMs are variable and incompletely characterized; the most frequent clinical presentations are intracranial hemorrhage and seizures, with other presentations including headaches or focal neurological deficits related to the location of the AVM (visual disturbances or speech disturbances). [2] [3] [4] [5] [6] [7] Although the hemorrhagic risk of giant AVMs has yet to be quantified, the association of smaller lesion size with higher risk of hemorrhagic presentation has previously been concluded by many studies. [8] [9] [10] [11] [12] [13] Consequently, the hemorrhagic risk associated with giant AVMs is theoretically lower compared with that for small to moderate-sized AVMs.
Treatment of giant AVMs remains controversial. The SpetzlerMartin grading system provides an intuitive method of categorizing AVM patients based on the risk associated with surgical intervention. 14 Most giant AVMs are high-grade lesions (grade IV and V); they typically demonstrate partial or complete involvement of eloquent brain regions and are therefore associated with significant treatment risk. 2, 3, 5 Because of the high treatment risk and low hemorrhagic rate associated with these lesions, conservative management has generally been recommended. 15 Treatment is usually reserved for patients with relatively acceptable treatment risks combined with increased hemorrhagic risk or persistent debilitating symptoms. 2, 3, 6 Despite general consensus on management strategy, the natural history of giant AVMs is poorly understood because of the rarity of these lesions. The present study is aimed at further clarifying long-term prognosis in patients with giant brain AVMs after intervention or conservative management.
METHODS Patient Population and Data Collection
We performed a retrospective review of all patients diagnosed with AVMs seen at our institution from January 1990 to December 2013. The study protocol was approved by our Institutional Review Board for Human Research. All patients diagnosed with a single intracranial AVM with maximum diameter $6 cm on magnetic resonance imaging or digital subtraction angiography were included. Patients with multiple AVMs, hereditary hemorrhagic telangiectasia, or unobtainable data were excluded from the study.
Patient baseline demographic, clinical, and angiographic data were collected. Hemorrhage presentation was defined as hemorrhage that could be attributed to AVM rupture. Two distinct groups of management strategies were predefined: a conservative group and an intervention group, which included patients who underwent surgical resection, radiosurgery, embolization, or a combination of these treatments. The follow-up period was defined as the interval between the first treatment and last follow-up for the intervention group. For the conservative management group, the follow-up period was defined as the interval between the diagnosis of AVM and last follow-up. Subsequent hemorrhage risk was defined as hemorrhage during the observation period or posttreatment follow-up. We also observed that some patients who underwent conservative management eventually crossed over to the intervention group. Therefore, to evaluate the impact of management strategy on control of subsequent hemorrhage, we regrouped the study cohort on the basis of the initial treatment recommendation. For patients with an initial recommendation of conservative management who eventually crossed over to the intervention group, the follow-up period was defined as the interval between diagnosis and treatment. Subsequent risk of hemorrhage after treatment or conservative management was represented as an annualized rate. Functional outcome at last follow-up was analyzed with the modified Rankin Scale (mRS). Patient symptoms after treatment and complications were evaluated on the basis of their presence at the last follow-up.
Criteria for Selection of Treatment
Symptom management such as headache or seizure medication was generally initiated for patients with unruptured presentations, and patients were recommended for close follow-up in outpatient clinics. Selected patients with relatively lower treatment risk combined with intractable progressive seizures or subsequent hemorrhage were suggested to undergo intervention.
The majority of patients with planned treatment of the AVM underwent multimodality treatment with embolization followed by radiosurgery. Planned surgical resection was found in only 1 case in which a patient with giant right occipital AVM was offered both staged surgical resection and conservative management with a suggested preference for the latter option, but the patient selected surgical treatment of the AVM despite anticipation of postoperative left homonymous hemianopsia. One patient underwent emergency surgical resection as a result of a retained catheter for attempted embolization. Other patients in the surgical arm were selected for surgery because of sudden intracranial hemorrhage. All microsurgical procedures were performed with continuous monitoring of electroencephalogram and somatosensory evoked potential. Patients with persistent seizures or progressive neurological deficits who were deemed unsuitable for surgical resection were recommended for radiosurgery. Radiosurgery was performed with the Leskell Gamma Knife (Elekta, Stockholm, Sweden) or with linear accelerator-based hypofractionated stereotactic radiotherapy.
Statistical Analysis
Baseline characteristics were compared between the conservative group and intervention group. All variables were summarized through the use of descriptive statistics. The Mann-Whitney U (Wilcoxon) test was used for continuous variables with nongaussian distribution; the Student t test was used otherwise for continuous variables with gaussian distribution. For categorical variables, either the Fisher exact test or the x 2 test was used.
Subsequent hemorrhagic risk between the 2 groups was evaluated descriptively with the use of annualized patient years. An annualized rate was calculated by dividing the number of subsequent hemorrhages at follow-up by total patient-years. A Poisson rate test was used to compare the annualized rate between the 2 management groups. Kaplan-Meier survival curve was used to assess progression to the first subsequent hemorrhage; the Mantel-Cox log-rank test was used to determine predictive factors. Statistical significance was defined as P , .05, with P values reported as 2 sided. All statistical analyses were performed with R Statistical Software (version 3.1.1; R Foundation for Statistical Computing, Vienna, Austria).
RESULTS

Baseline Characteristics
A total of 55 patients (8.1%) with giant AVMs (Table 1) were included from our institutional database of 683 patients. Twentyfour patients (43.6%) were conservatively managed. The mean age was 29.6 6 14.6 years: 33.8 6 16.6 years in the conservative group (n = 24, 43.6%) and 26.4 6 12.2 years in the intervention group (n = 31, 56.4%). Twelve patients (21.8%) presented with hemorrhage: 3 patients (12.5%) in the conservative group and 9 patients (29.0%) in the intervention group (P = .21). The majority of patients presented with seizure (n = 31, 56.4%) or headaches (n = 25, 45.5%). Spetzler-Martin grades of all AVMs were as follows: 2 grade III lesions (3.6%), 15 grade IV lesions (27.3%), and 38 grade V lesions (69.1%). The average size of all AVMs was 7.4 6 1.6 cm (range, 6.0-14.0 cm). Compared with the intervention group, the conservative group had significantly larger AVMs (7.8 cm; P , .05) with more frequent involvement of the temporal lobe (P = .02). Other angiographic features were similar between the 2 groups and are presented in Table 1 .
Clinical Features and Outcomes
Thirty-five patients (63.6%) from the initial cohort were continuously followed up clinically and angiographically in our institution, with an average follow-up of 11.8 6 10.0 years (range, 0.2-37.7 years). Baseline characteristics of the followed patients are illustrated in the Supplemental Digital Content 1 (see Table, http://links.lww.com/NEU/A833). The intervention group was followed up for 10.6 6 7.9 years (range, 0.3-33.5 years) in contrast to 13.7 6 13.3 years (range, 0.2-37.7 years) for the conservative group (P = .45). Although 19 patients (54.3%) were initially recommended for conservative management, only 13 patients (37.1%) were eventually managed conservatively without any interventional treatment. Six patients crossed over from conservative management to treatment: 4 patients with intractable seizures and 2 who experienced subsequent hemorrhages during the observation interval. Of the 20 patients who were lost to follow-up or with unobtainable follow-up data, 1 patient died of rehemorrhage after embolization and radiation, 10 patients were lost to follow-up after a second opinion consultation regarding AVM treatment, 4 patients were lost to followup after radiosurgery, and 2 patients achieved complete surgical obliteration and were discharged home. Three patients were followed up in nonneurosurgical departments at our institution and therefore were not evaluated in terms of neurological outcomes.
Of all patients with follow-up who eventually received treatment of the AVM (n = 22), only 3 patients (9.1%) achieved angiographic obliteration at the last follow-up: 2 patients treated with repeated embolization and radiosurgery and another patient treated with surgical resection. Treatment outcomes of each modality for patients in the intervention group are described in detail in Table 2 . Average patient mRS scores at the last follow-up appeared to be worse in the intervention group compared with the conservative group (Table 3) , although the difference was not significant (P = .16). Significantly fewer patients in the intervention group experienced seizures at the last follow-up compared with the conservative group (P , .05). The probability of follow-up hemorrhage was similar between the 2 groups (P . .99). A comparison of survival probability for free of first subsequent hemorrhage between the conservative management and intervention groups is shown in Figure 1 ; no difference was observed (P = .78).
Despite similar baseline mRS scores (1.3 6 1.0 for conservative group vs 1.7 6 1.1 for intervention group; P = .27), there was a trend of more patients with optimal outcome (mRS , 2, n = 9 [69.2%] vs n = 8 [36.4%]; P = .06) in the conservative group compared with the intervention group at the last follow-up. In a comparison of the mRS score at the last follow-up with those at baseline, the majority of patients (53.8%, n = 7) in the conservative group had the same mRS score, whereas 23.1% (n = 3) worsened and 23.1% improved (n = 3). In contrast, the majority of patients (50.0%, n = 11) experienced worsened mRS scores in the treatment group, whereas 36.4% (n = 8) and 13.6% (n = 3) of patients demonstrated improved or unchanged mRS scores before and after treatment (Figure 2 ), respectively.
To evaluate the effect of initial treatment decision on subsequent hemorrhagic risks, we regrouped patients on the basis of initial treatment recommendation. With this new grouping method, 19 patients were initially recommended for conservative management, and 16 patients were recommended for intervention. Five patients (26.3%) in the new conservative group experienced a total of 7 subsequent hemorrhages during a follow-up period of 256.71 patient-years, whereas 5 patients (31.3%) in the new intervention group experienced a total of 9 subsequent hemorrhages during a follow-up period of 218.05 patient-years. This translated to an annualized hemorrhagic rate of 2.7% per patient per year in the conservative group and 4.1% per patient per year in the intervention group (Table 4) . The overall annualized hemorrhage rate was 3.4%.
DISCUSSION General Characteristics and Natural History
Giant AVMs are a distinct subset of vascular malformations that have been incompletely characterized. Our present study included 55 patients with giant AVMs (8.1%) from our database of 683 patients, with 35 patients actively followed up in our institution, representing one of the largest series assembled to date with a specific focus on giant AVMs. 2, 3, 7, 15 Our prevalence of 8.1% for giant AVMs is higher than the reported prevalence of 3.1% to 4.1%. 2, 3, 16 This may be partially attributable to reporting bias; the majority of these studies calculated the prevalence of giant AVMs in the context of microsurgical series, so the true prevalence of giant AVMs might be underestimated because most giant AVMs were not eligible for interventional treatment and therefore were not included in the analysis. In a recent multi-institutional analysis by Kim et al, 17 the prevalence of high-grade AVMs (grades IV and V) were found to be within the range of 2% to 16%, and our result falls within this range. From our results, patients with giant AVMs presented mostly as adults (age, 29.6 years), with seizures (56.4%) and headache (45.5%) as the presenting symptom leading to diagnosis. Fewer patients presented with hemorrhage (21.8%) compared with the reported risk of hemorrhagic presentation of 30% to 82% in most AVM populations. 10, [18] [19] [20] [21] [22] Although the underlying mechanism is not completely understood, our findings are compatible with the 
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existing notion that larger AVMs confer a lower risk of hemorrhagic presentation. 9, 10, 23 The higher seizure occurrence may be explained by chronic peripheral brain ischemia resulting extensive steal phenomenon from predominant shunting mechanisms in giant AVMs. [24] [25] [26] Our result also suggested that the conservative group had larger AVMs compared with the intervention group (7.8 vs 7.1 cm; P , .05); however, the clinical significance of 0.7 cm difference is debatable.
The rarity of giant AVMs has limited previous studies. Because most patients with giant AVMs were symptomatic and actively sought definitive treatment of the causative lesion, they were more likely to opt for a second opinion and subsequently were lost to follow-up when they were recommended for conservative management. This phenomenon was observed in our study population, of which 10 patients (18.2%) were eventually lost to follow-up after they were encouraged to seek a second opinion. For the remaining 35 patients, the overall annualized rate of hemorrhage was 3.4%, with 2.7% and 4.1% in patients undergoing observation and intervention, respectively. The risk of subsequent hemorrhage in patients recommended for observation fell within reported rates of 1.9% to 4.61% in previous studies. 8, 12, 13, 16, 18, 19, [27] [28] [29] [30] Of note, although a relatively higher annual hemorrhagic rate was observed in the intervention arm, the difference was likely a result of preselection of high-risk patients. Nevertheless, no significant difference for hemorrhagic risk was observed between the 2 arms.
Giant AVMs and Spetzler-Martin Grading
The Spetzler-Martin grading scale is a widely used tool for stratification of surgical risk in AVM patients based on lesion size, location, and venous drainage pattern. 2, 3, 7, 14 According to the grading scheme, giant AVMs can be categorized into 3 grades: grades III, IV, and V. Grade IV and V AVMs were referred to in the 3-tiered classification proposed by Spetzler and Ponce 31 as class C AVMs, which represented the highest risk for treatment. These AVMs, generally referred to as high-grade AVMs in the literature, demonstrated significantly worse prognosis than other lower-grade AVMs. In contrast, grade III giant AVMs were rarely seen in any study and were considered to be nonexistent. Lawton et al 32 suggested that these AVMs only theoretically exist with unclear surgical risk because no grade III giant AVMs were found in their study cohort of 174 consecutive grade III brain AVM patients. Our present study included 2 patients (3.6%) with grade III giant AVMs. Both AVMs were irregularly shaped and located in the medial posterior parietal lobe, sparing both somatosensory cortex and occipital lobe, with superficial drainage to sagittal sinus by cortical veins. Similarly, Chang et al 2 included 1 patient (2.0%) and Zhao et al 3 included 5 patients (12.5%) with grade III AVMs in their giant AVM studies. Therefore, evidence suggests that this subcategory of AVM rarely exists.
The clinical relevance of grade III AVMs needs to be further investigated, and the surgical risk associated with these lesions should be cautiously interpreted. As suggested by Lawton, 32 S2V1E0 (S is the score for size, V is the score for deep venous drainage, and E is the score for eloquence) and S2V0E1 demonstrated a higher surgical risk than S1V1E1. Compared with S1V1E1 AVMs, an increase in AVM size surpassed the impact of an increase in deep drainage or eloquence. Therefore, with the assumption that size is the predominant factor for prediction of patient prognosis after surgical resection, giant grade III AVMs (S3E0V0) may represent the highest-surgical-risk subgroup among all grade III AVMs. In our study, the 2 patients with grade III AVMs were not recommended for any surgical treatment and were eventually treated with radiosurgery. Although both patients demonstrated a good functional outcome at the last follow-up, none of the lesions were obliterated. The extensive challenge in surgical management of these lesions should be noted, and grade III giant AVMs should at least be considered as an outlier within grade III AVMs, if not grouped into a higher-risk category altogether.
Management Strategy of Giant AVMs
Management needs to be individualized, given the heterogeneity of the angioarchitecture and clinical manifestations of giant AVMs. Giant AVMs are generally associated with significant treatment risk and relatively low hemorrhagic risk. Given the low obliteration rate and prolonged treatment course, patients still suffer considerable risk of subsequent hemorrhage from incompletely treated lesions. In addition, the possible complications of each treatment must be carefully weighed. Therefore, from a riskbenefit perspective, most patients should still be recommended for conservative management, and intervention should be cautiously considered only in highly selected patients. Zhao et al 3 suggested that patients with significantly higher risk of subsequent hemorrhage as a result of ruptured presentation, associated aneurysms, or residual AVMs should be considered for treatment. The authors further suggested that patients with intractable seizures or progressive neurological deficits should also be treated. Comparable criteria were adopted in our present study and by Chang et al 2 for patient treatment selection. In regard to the selection of treatment modality, because of the complexity of these AVMs, most studies have suggested a multimodality approach, which includes a combination of embolization, radiosurgery, and microsurgery. 2, 3 Common treatment regimens include embolization only, embolization followed by microsurgery, embolization followed by radiosurgery, and a combination of all 3 modalities. 33 Preoperative embolization or radiosurgery has been demonstrated to effectively reduce the size of the AVM and to downgrade the AVM to a surgical acceptable grade. 2, 3, 34 In contrast, the application of embolization before radiosurgery has 
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been controversial and was previously demonstrated to have a negative impact on obliteration rate in radiosurgical series. 35 Staged radiosurgery alone has been shown to successfully control seizure and to obliterate the AVM. 34, 36 Acceptable prognosis has been reported in previous studies, with a mortality rate of 10% to 15%, obliteration rate of 58% to 96.5%, and good or excellent functional outcomes at follow-up in 51% to 77.5%. 2, 3, 34 However, it is noteworthy that these results were achieved after prudent patient selection, which excluded elderly patients accompanied with significant comorbidities and patients with inoperable AVMs. 34 Furthermore, for most treated AVM series, giant AVMs were excluded because of excessive treatment risk, which resulted in underreporting. Therefore, it is likely that current results are biased toward optimal outcome after treatment of giant AVMs, and careful interpretation of these results is warranted before the results are applied in treatment decisions.
Limitations
Several limitations are associated with this study. First, similar to most AVM studies, this is a retrospective, single-institution study. Attrition bias was associated with this study when patient data were retrospectively reviewed. Similar to most AVM studies, our study suffers a potential selection bias, in which AVMs with lower treatment risk and higher hemorrhagic risk may be more prone to be selected for intervention. It is also possible that those lost to follow-up in our patient cohort represent a harder-to-treat giant AVM population and therefore posed treatment selection bias in our study. We also observed a number of patients who sought multiple opinions and were eventually followed up and treated in our institution; these patients also represented a cohort with extensive management challenges. Although the treatment group comprised patients with slightly smaller AVMs, other hemorrhagic risk factors such as ruptured presentation, aneurysms, and deep venous drainage are similar. In addition, Spetzler-Martin grades were similar across the 2 comparison groups, suggestive of a relatively even distribution of treatment risk factors between the conservative and intervention management groups, which enabled us to perform some comparisons.
CONCLUSION
Giant intracranial AVMs are dynamic and complex vascular malformations that require careful consideration of the patients' clinical presentations and lesion angioarchitecture. We observed poor angiographic obliteration rate and similar hemorrhagic risks between the 2 management strategies. In addition, functional outcome is likely to be the same or better when patients are 
